TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Profile improvements
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Gastric intramucosal‐arterial PCO(2) difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Normalization of serum level of albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved stability of the circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduced plasma levels of cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in knowledge about diabetic eye disease
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sustained HBeAg seroconversion with clearance of HBV-DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse effects of IFN
Endpoint domain: Adverse events/effects
Primary endpoint: Relapse of Hodgkin's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HSV-2 acquisition rate
Endpoint domain: Mortality/survival
Primary endpoint: Risk of HSV-2 transmission
Endpoint domain: Mortality/survival
Primary endpoint: 6-month quit rate
Endpoint domain: Mortality/survival
Primary endpoint: Complete closure of UCFs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnea incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to repeat the exam
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: E‐selectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GAD65Ab level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic accuracy of BHR tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory functional ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived confidence of anesthesiologists
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived intelligence of anesthesiologists
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Likelihood of choosing anesthesiologist to care for family member
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Blood Velocity (MBV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak Blood Velocity (PBV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hot flash severity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: hot flash frequency
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: EuroQol
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Response rates for oVEMPs and cVEMPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latencies and amplitudes of oVEMPs and cVEMPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in total MADRS score at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean titres (GMTs) of anti-PRP antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants with anti-PRP antibody titres > or = 1.0 microg/ml after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Correct torque values computed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of edema in soft tissue
Endpoint domain: Adverse events/effects
Primary endpoint: Negative predictive value of the SLEEP Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of death or composite cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Clinical improvement (≥20% reduction in PANSS total score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of preexisting extrapyramidal symptoms (EPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Incidence of tardive dyskinesia (TD)
Endpoint domain: Adverse events/effects
Primary endpoint: oxygen need
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: more eating episodes per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: more servings from the dairy product food group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower percentage of energy from protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCEs (sister chromatid exchanges)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MN (micronuclei)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urine sodium goal achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urine cotinine negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3-5 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: CRP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of participants quitting
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: pad tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: DHA levels of erythrocyte lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: P100 wave latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: satisfactory motor outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of recovery of full consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of parasite clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CFT reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of DGE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in conduct problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bond degradation after 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interfacial nanoleakage expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cessation of smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean plasma concentrations of prilocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average pain-BSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall IBS BSS severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diarrhoea-BSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients with at least 50% pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRC recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: S(CT)O(2) in both prefrontal lobes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of pinprick analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to perform 'deep knee bends' and 'straight leg raises'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mood and quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Levels of inflammatory factors (e.g., interleukin-6, tumor necrosis factor-α, C-reactive protein)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Distribution of ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: VDS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amelioration of extrapyramidal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of venous thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: occurrences of root fracture, gingival laceration, tooth mobility, lingual bone plate fracture, jaw fracture, and dislocation of temporomandibular joint
Endpoint domain: Adverse events/effects
Primary endpoint: occurrences of lower lip numbness, dry socket, facial swelling and limitation of mouth opening
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first passage of stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Surgeon's cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Intraoperative events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Locomotive strain-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative morphine consumption 24 h after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lamotrigine area under the concentration‐time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration of lamotrigine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (fatigue, dizziness, transaminase elevations)
Endpoint domain: Adverse events/effects
Primary endpoint: Probing attachment level (PAL) gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in brain volume over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Planter pressure distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: seven-day point prevalence abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cotinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average number of cigarettes smoked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse cardiovascular event (MACE)
Endpoint domain: Mortality/survival
Primary endpoint: average pain NRS at 24 hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average morphine consumption at 24 hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 scores at two, four, eight, and 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in carer burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Reduction in forearm flexor spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: median cure time
Endpoint domain: Mortality/survival
Primary endpoint: appearance of new HPV lesions
Endpoint domain: Adverse events/effects
Primary endpoint: number of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: unnecessary invasive angiography rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Self‐rated throat irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocyte and total leukocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Correct diagnosis of RA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awareness of RA diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 28-day curative ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Commitment to smoking behavior change
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: seroresponse rate of anti-rotavirus IgA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PD3 GMT of anti-rotavirus IgA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cancer-related primary care visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of participants randomised
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Complete response rates (no emetic episodes plus no rescue medication)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients free of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of CINV on daily activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to achieve discharge criteria
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Initial claudication distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in power due to withdrawals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the odds of RBP <1.17 μmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Probing depth (PD) decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high-impact activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MWT mean sleep latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGIC rating improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in number of social needs reported
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Improvement in child's health as reported by caregivers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in the appearance of pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: global quality of life improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Local recurrence-free survival (LRF)
Endpoint domain: Mortality/survival
Primary endpoint: Plasma triglyceride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BMIz reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Secretion of TRLs without apo E or apo C‐III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TRL fractional catabolic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of TRLs cleared
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to > or =1-mm ST-segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Angina episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Basal potential difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGE2 mucosal generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image quality comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of renal vasculature prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total systemic morphine equivalent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response according to EASL criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual tumor identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adverse events of grades 1-3
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of (‐)‐cisapride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0, infinity) of (‐)‐cisapride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of (+)‐cisapride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thiopental dose requirement reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution volumes of thiopental
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution clearances of thiopental
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 11-SCT time for identifying early knee OA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: incidence of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: incidence rates of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: β(2)-adrenergic receptor sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NTRK3 mRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NTRK3 protein immunoreactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain during bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete healing after 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function as measured by FIM/FAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MPOPS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall clinical remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall mucosal healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year sustained clinical remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete flap closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: VAS (pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8-hydroxy-2-deoxyguanosine (8-OHdG) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of pacemaker implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term vagal reflex attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in spontaneous syncope episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UKU Psychic Side Effects subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in headache intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: beta‐NGF and TrKA expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence of inflammatory change outside the joint cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of leukopenia
Endpoint domain: Adverse events/effects
Primary endpoint: rate of severe infections
Endpoint domain: Adverse events/effects
Primary endpoint: levels of follicle-stimulating hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cause-specific death
Endpoint domain: Mortality/survival
Primary endpoint: Mean reduction in FAD volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of pre-treatment pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adrenocorticotropic hormone plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postoperative recovery time
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: HVA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MHPG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of verified DVTs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of local hematoma or local infections
Endpoint domain: Adverse events/effects
Primary endpoint: Circulating BCFAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Circulating BCAAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin resistance (assessed by HOMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: pre-hospital ROSC
Endpoint domain: Mortality/survival
Primary endpoint: favorable neurological outcome
Endpoint domain: Mortality/survival
Primary endpoint: Intent to engage in weight-related behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reduced levels of social anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reduced levels of trait anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing